Morgan Stanley’s Adial Pharmaceuticals ADIL Stock Holding History

Morgan Stanley’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$128	Hold	50	–	–	﹤0.01%	7907
2026 Q1	$90	Buy	+50	New	+$176	﹤0.01%	7816
2025 Q4	–	Hold	0	–	–	–	8171
2025 Q3	–	Hold	0	–	–	–	8137
2025 Q2	–	Hold	0	–	–	–	8060
2025 Q1	–	Hold	0	–	–	–	8022
2024 Q4	–	Sell	-12	Closed	-$312	–	7912
2024 Q3	$309	Buy	12 +10	+500%	+$261	﹤0.01%	7347
2024 Q2	$45	Buy	2 +1	+100%	+$38	﹤0.01%	7527
2024 Q1	$20	Buy	+1	New	+$37	﹤0.01%	7720
2023 Q4	–	Sell	-1	Closed	-$55	–	7723
2023 Q3	$58	Hold	1	–	–	﹤0.01%	7479
2023 Q2	$111	Hold	1	–	–	﹤0.01%	7488
2023 Q1	$187	Hold	1	–	–	﹤0.01%	7521
2022 Q4	$124	Sell	1 -1	-50%	-$175	﹤0.01%	7681
2022 Q3	$0	Buy	2 +1	+100%	+$451	﹤0.01%	7678
2022 Q2	$1K	Hold	1	–	–	﹤0.01%	7651
2022 Q1	$1K	Hold	1	–	–	﹤0.01%	7817
2021 Q4	$1K	Sell	1 -63	-98%	-$124K	﹤0.01%	7841
2021 Q3	$173K	Buy	64 +63	+6,300%	+$132K	﹤0.01%	6076
2021 Q2	$1K	Sell	1 -7	-88%	-$10.6K	﹤0.01%	7581
2021 Q1	$13K	Buy	8 +7	+700%	+$10.6K	﹤0.01%	6861
2020 Q4	$1K	Hold	1	–	–	﹤0.01%	6929
2020 Q3	$1K	Hold	1	–	–	﹤0.01%	6636
2020 Q2	$1K	Hold	1	–	–	﹤0.01%	6507
2020 Q1	$1K	Hold	1	–	–	﹤0.01%	6443
2019 Q4	$1K	Hold	1	–	–	﹤0.01%	6548
2019 Q3	$1K	Hold	1	–	–	﹤0.01%	6527
2019 Q2	$1K	Hold	1	–	–	﹤0.01%	6511
2019 Q1	$2K	Hold	1	–	–	﹤0.01%	6439
2018 Q4	$3K	Hold	1	–	–	﹤0.01%	6365
2018 Q3	$1K	Buy	+1	New	+$2.08K	﹤0.01%	6607

Other funds holding ADIL

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCM

Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley's ADIL Position: Q2 2026 in Review

Morgan Stanley held its Adial Pharmaceuticals (ADIL) position steady in Q2 2026 at 50 shares worth $128. The position accounts for ﹤0.01% of the portfolio, ranked #7907.

Morgan Stanley first reported a position in ADIL in Q3 2018 and has held it in 26 quarters since. The position peaked at $173K in Q3 2021. 17 funds tracked by Wall St. Rank hold ADIL as of Q2 2026.

Morgan Stanley held 50 shares of Adial Pharmaceuticals worth $128 as of Q2 2026.
Morgan Stanley left its Adial Pharmaceuticals share count unchanged in Q2 2026.
Adial Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7907 holding.
Morgan Stanley first reported a position in Adial Pharmaceuticals in Q3 2018 and has held it in 26 quarters since.
Morgan Stanley's Adial Pharmaceuticals position peaked at $173K in Q3 2021.
17 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.